美國居民不適用 XM 服務。

Pfizer wins pause on Moderna's 19 patent lawsuit



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Pfizer wins pause on Moderna's COVID-19 patent lawsuit</title></head><body>

By Blake Brittain

April 12 (Reuters) -Moderna's MRNA.O patent lawsuit claiming Pfizer PFE.N and BioNTech 22UAy.DE copied its COVID-19 vaccine technology will be put on hold while the U.S. Patent Office determines whether two of the three Moderna patents at issue are valid, a Massachusetts federal court said on Friday.

U.S. District Judge Richard Stearns stayed the closely watched case over Moderna's objections after determining that the Patent Office's rulings would "simplify" the patent-infringement lawsuit, according to an entry on the court's docket.

A Moderna spokesperson said in a statement that the company was disappointed with the pause but "continues to believe in the strength and validity of its patents." Representatives for Pfizer and BioNTech did not immediately respond to requests for comment.

Moderna accused Pfizer and BioNTech's vaccine of violating its patent rights in messenger-RNA technology in a 2022 lawsuit. The case is one of several brought by biotech companies seeking patent royalties from the blockbuster COVID-19 vaccines.

Moderna earned $6.7 billion in revenue from its vaccine Spikevax last year, while Pfizer made $11.2 billion from sales of its vaccine Comirnaty. Sales of both vaccines declined significantly last year from 2022.

Defendants frequently turn to the U.S. Patent Office's Patent Trial and Appeal Board, which reconsiders the validity of patents issued by the office, as an alternative path to fend off infringement claims. Pfizer and BioNTech asked the board to review two Moderna patents last year, arguing they were "unimaginably broad" and cover a "basic idea that was known long before" their invention date of 2015.

The board agreed to review both patents last month. Review proceedings generally last between one year and 18 months, and Pfizer asked the Massachusetts court to pause Moderna's infringement case during the office proceedings.

Moderna opposed Pfizer's request, arguing a stay would be "highly prejudicial" and unnecessarily delay an infringement trial that Stearns has said could be held in autumn or early winter.

Stearns granted Pfizer's request on Friday. The judge said that the board review would streamline the infringement case and that a pause would not hurt Moderna financially or affect its ability to present evidence at trial.


The case is ModernaTX Inc v. Pfizer Inc, U.S. District Court for the District of Massachusetts, 1:22-cv-11378.

For Moderna: William Lee, Emily Whelan, Kevin Prussia, Andrew Danford and Amy Wigmore of Wilmer Cutler Pickering Hale & Dorr

For Pfizer: Thomas Selby, Stan Fisher and Kathryn Kayali of Williams & Connolly

For BioNTech: Bruce Wexler, Eric Dittmann, Young Park and Ashley Mays-Williams of Paul Hastings


Read more:

Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine

Pfizer, BioNTech challenge Moderna COVID-19 vaccine patents at US Patent Office



Reporting by Blake Brittain in Washington

</body></html>

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明